UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): ~~June~~August 34, 2025

CVRx, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-40545		41-1983744
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

9201 West Broadway Avenue, Suite 650

Minneapolis, MN 55445

(Address of principal executive offices) (Zip Code)

(763) 416-2840

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange

on which registered

Common stock, par value $0.01 per share

CVRX

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 52.0702. ~~Submission~~Results of ~~Matters~~Operations toand aFinancial ~~Vote of Security Holders~~Condition.

On ~~June 3~~August 4, 2025, CVRx, Inc. (the “Company”) issued ~~held~~a ~~its~~press ~~2025~~release ~~annual~~announcing ~~meeting~~its offinancial ~~stockholders~~results (for the ~~“Annual~~quarter ~~Meeting”)~~ended June 30, 2025. ~~Voting~~A ~~results for~~copy ~~each~~of ~~matter~~the ~~submitted~~press torelease ais ~~vote~~attached atas Exhibit 99.1 ~~the~~and ~~Annual~~is ~~Meeting~~incorporated ~~are~~herein ~~provided~~by ~~below~~reference.

~~Proposal 1.~~The ~~Election~~information ofcontained ~~Directors.~~in ~~The~~this ~~two~~Item ~~nominees~~2.02, ~~for~~including ~~Class~~Exhibit I99.1, is ~~director~~being ~~were~~furnished ~~elected~~and shall not be deemed to ~~serve~~be ~~until~~“filed” with the ~~2028~~Securities ~~annual~~and ~~meeting~~Exchange Commission for purposes of Section 18 ~~stockholders~~of ~~and~~the ~~until~~Securities ~~their~~Exchange ~~successors~~Act ~~are~~of ~~duly~~1934, ~~elected~~as ~~and~~amended ~~qualified~~(the “Exchange Act”), or otherwise subject to the liabilities of that section and is not incorporated by reference into any filing under the ~~votes~~Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as expressly set forth by specific reference in ~~the~~such ~~table~~a ~~below~~filing.

Nominee	For	Withheld	Broker Non-Votes
Kevin Ballinger	15,182,085	848,042	6,965,421
Mitch Hill	14,338,976	1,691,151	6,965,421

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

~~Proposal 2.~~On ~~The~~August ~~stockholders~~4, ~~ratified~~2025, the Company ~~appointment~~announced ofthat ~~Grant~~its ~~Thornton~~Board ~~LLP~~of asDirectors (the ~~Company’s~~“Board”) ~~independent~~appointed ~~registered~~Brent ~~public~~Binkowski ~~accounting firm~~as ~~for~~Chief ~~the~~Operating ~~fiscal~~Officer, ~~year~~effective August ~~ending December 31~~11, 2025~~, by the votes set forth in the table below~~.

For		Against		Abstain
22,940,803		52,397		2,348

Mr. Binkowski, age 56, previously served as Vice President of Operations – Interventional Urology of Coloplast Corp., a healthcare products company, from June 2020 to August 2025. Prior to Coloplast, Mr. Binkowski held positions of increasing responsibility in engineering, manufacturing and operations at Teleflex Incorporated, Vascular Solutions, Inc. (which was acquired by Teleflex), CeloNova BioSciences, Inc., and American Medical Systems – Ireland. The Compensation Committee of the Board approved the following compensation for Mr. Binkowski: (i) an initial annual base salary of $405,000, (ii) a target cash incentive award of 50% of base salary (which will be pro-rated for fiscal 2025), (iii) initial equity awards consisting of 74,900 stock options and 16,600 restricted stock units, which will have terms consistent with the Company’s current forms of equity awards, and (iv) a sign-on bonus in recognition of the annual incentive opportunity he will forfeit from his current employer in the amount of $50,000 that is subject to repayment if Mr. Binkowski resigns or is terminated for cause prior to the first anniversary of his hire date. Mr. Binkowski will receive the Company’s standard form of severance agreement for executive officers.

~~SIGNATURES~~Item 9.01. Financial Statements and Exhibits.

~~Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.~~(d) Exhibits

	CVRx, Inc.
Exhibit No.		Description
Date: June 5, 2025	By:	/s/ Jared Oasheim
99.1		Press release of CVRx, Inc., dated August 4, 2025
		Name: Jared Oasheim
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
		Its: Chief Financial Officer

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	CVRx, Inc.

Date: August 4, 2025	By:	/s/ Jared Oasheim
		Name: Jared Oasheim
		Its: Chief Financial Officer

Filing Compare · CVRx, Inc.